编号：2016-005 证券代码：300267 证券简称：尔康制药 湖南尔康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-----------------------------------------------------|---------------------------------------------------| | | | | | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □ 现场参观 □其他 | □路演活动 （请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 1、招商基金 2 、东兴证券 缪牧一 3 、浙商资管 戴颖 | 滕越 | | 时间 | 2016 年 9 月 14 | 日 | | 地点 | 公司会议室 | | | 上市公司接待人员姓名 | 董事、副总经理 董事会秘书 | 王向峰先生 罗琅先生 | | | | | | 投资者关系活动主要内容 介绍 | 1 车间。 | 、董 ...

编号：2016-004 证券代码：300267 证券简称：尔康制药 湖南尔康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □ 现场参观 | □路演活动 | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 1、海通证券 2 、海通证券 3 、光大证券 4 、光大证券 5 、广州证券 6 、国信证券 7 、银河证券 8 、兴证投资 9、上海从容投资 ...

证券代码：300267 证券简称：尔康制药 湖南尔康制药股份有限公司投资者关系活动记录表 编号：2019-002 | --- | --- | --- | |-----------------------------|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 | □路演活动 | | | √ 现场参观 □其他 | （请文字说明其他活动内容） | | 参与单位名称及人员姓名 | | 财富证券谭谦、邹林原、陈骏雄、贺理、陈金鑫、徐延照等人；中泰 证券罗婷婷、张腾、李文辉、孔婷等人；湖南华州投资董建平、向 昱；信持力私募黎意平；部分个人投资者 ...

编号：2017-001 证券代码：300267 证券简称：尔康制药 湖南尔康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|---------------------------|------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □ 现场参观 | □路演活动 | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及人员姓名 | | 中邮创业基金管理股份有限公司 投研部负责人 黄礴 | | 时间 | 2017 年 11 月 24 | 日 | | 地点 | 公司会议室 | | | 上市公司接待人员姓名 | 董事长 董事会秘书 | 帅放文先生 罗琅先生 | | 投资者关系活动主要内容 介绍 | | | | | | 董事长帅放文先生和董秘罗琅先生与调研人员的沟通 | | | 交流主要内容如下： | ...

编号：2019-001 证券代码：300267 证券简称：尔康制药 湖南尔康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-----------------------------|----------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 | □路演活动 | | | □ 现场参观 □其他 | （请文字说明其他活动内容） | | 参与单位名称及人员姓名 | | 深圳市君如资产管理顾问有限公司 王腾 | | 时间 | 2019 年 3 月 8 日 | | | 地点 | 公司会议室 | | | 上市公司接待人员姓名 | 董事会秘书 | 施湘燕 | | 投资者关系活动主要内容 介绍 | | | | | | 董事会秘书施湘燕女士与调研人员的沟通交流主要内 | | | 容如下： | | | | 1 | 、公司淀粉囊产品同比下降原因 ...

湖南尔康制药股份有限公司 2022 年第三季度报告 证券代码：300267 证券简称：尔康制药 公告编号：2022-034 湖南尔康制药股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 是 □否 追溯调整或重述原因 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------------------------|-----------------|-------------------|------ ...

Group 1: Event Details - The company will participate in the "2022 Investor Online Collective Reception Day" organized by Hunan Securities Regulatory Bureau and others [1] - The event will be held online via the "Panjing Roadshow" platform on September 29, 2022, from 15:30 to 17:00 [1] - Investors can access the event through the website: http://rs.p5w.net/ [1] Group 2: Company Representatives - The company's Vice General Manager and Board Secretary, Mr. Gu Jishun, will be present for the online communication [1] - Securities Affairs Representative, Ms. Fan Yi, will also participate in the discussions with investors [1] Group 3: Investor Engagement - The event aims to enhance interaction and communication with investors, allowing them to gain a deeper understanding of the company's situation [1] - The company encourages widespread participation from investors [1]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥870,551,135.58, representing a 4.58% increase compared to ¥832,432,663.23 in the same period last year[20]. - The net profit attributable to shareholders of the listed company decreased by 67.82% to ¥30,088,115.38 from ¥103,286,458.37 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 76.34% to ¥20,453,800.23 from ¥89,417,356.64 in the same period last year[20]. - The net cash flow from operating activities was ¥68,063,584.22, down 57.42% from ¥157,267,075.66 in the previous year[20]. - Basic earnings per share decreased by 67.77% to ¥0.0146 from ¥0.0501 in the same period last year[20]. - The company's overall revenue increased by 4.58% year-on-year during the first half of 2022, despite challenges in the pharmaceutical industry[33]. - The pharmaceutical industry saw a decline in revenue of 0.6% and a profit drop of 27.6% for large enterprises in the first half of 2022[34]. - The operating costs increased by 25.97% to ¥655,273,811.78 from ¥520,169,606.85, indicating rising expenses[47]. - Research and development investment decreased by 11.49% to ¥20,410,389.00 from ¥23,060,643.70[47]. - The company reported a total of ¥135,113,770.38 in financial assets, with a fair value adjustment of ¥6,903,768.49[56]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,555,124,835.03, an increase of 2.27% from ¥5,431,979,242.78 at the end of the previous year[20]. - The total liabilities as of June 30, 2022, were CNY 578,127,762.41, up from CNY 558,277,304.57 at the start of the year, indicating a growth of about 3.00%[138]. - The company's total liabilities to total assets ratio as of June 30, 2022, was approximately 10.41%, up from 10.27% at the beginning of the year[138]. - The company's cash and cash equivalents at the end of the reporting period amounted to ¥804,615,166.47, representing 14.48% of total assets, an increase from 14.02% at the end of the previous year[52]. - Inventory increased to ¥826,999,582.27, accounting for 14.89% of total assets, up from 13.16% the previous year, indicating a 1.73% increase in proportion[52]. Business Operations - The company operates in three main business areas: excipients, active pharmaceutical ingredients (APIs), and finished drugs, with a focus on excipients as a leading domestic manufacturer[29]. - The excipients sector has shown growth, with the company developing a range of products to meet diverse customer needs[29]. - The company’s finished drug products include various injections and traditional Chinese medicine, enhancing its market presence through distribution channels[30]. - The company has adopted a "sales-driven production" model to align production with market demand[31]. - The company is responding to rising raw material prices by actively managing inventory and procurement strategies[30]. Corporate Governance and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[3]. - The company has not classified any non-recurring gains as recurring, maintaining transparency in its financial reporting[26]. - The company has received an environmental discharge permit, with the permit number 914309006828327274001P, and has conducted environmental impact assessments for all production projects[82]. - No administrative penalties were imposed on the company during the reporting period for environmental issues, indicating compliance with regulations[83]. - The company emphasizes employee rights protection, providing equal development opportunities and a comprehensive performance evaluation system[85]. Future Outlook and Strategy - The company plans to expand its production capacity for pharmaceutical intermediates and composite excipients, which may lead to management and marketing risks[70]. - The company plans to focus on expanding its market presence and enhancing its product offerings in the upcoming quarters[156]. - The company aims to improve its financial stability by optimizing its capital structure and reducing debt levels[156]. - The company is focusing on sustainability initiatives, with plans to invest in eco-friendly technologies[177]. Shareholder Information - The total number of shares is 2,062,604,870, with 31.11% (641,606,366 shares) being restricted shares and 68.89% (1,420,998,504 shares) being unrestricted shares[116]. - The largest shareholder, Shuai Fangwen, holds 41.38% of the total shares, amounting to 853,574,906 shares, with 640,181,179 shares being restricted[120]. - The company reported a total of 12,000,070 shares held in the employee stock ownership plan at the end of the reporting period, representing 0.58% of the total share capital[78]. Risk Management - The company is facing risks related to macro policy adjustments in the pharmaceutical industry, necessitating timely adjustments to management strategies[68]. - The company is exposed to foreign exchange risks due to increasing overseas projects and has established a management system for forward foreign exchange transactions[71]. - The ongoing COVID-19 pandemic has impacted the company's operations, prompting adjustments in business strategies and product structures[71].

Financial Performance - The company's operating revenue for Q1 2022 was ¥426,347,681.19, representing an increase of 11.09% compared to the same period last year[3]. - The net profit attributable to shareholders decreased by 49.45% to ¥22,533,577.51, down from ¥53,028,821.97 in the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 59.71% to ¥16,440,304.31[3]. - Net profit for Q1 2022 was CNY 19,785,501.01, a decrease of 59.00% from CNY 48,397,485.29 in Q1 2021[20]. - The net profit attributable to the parent company was CNY 22,533,577.51, down 49.51% from CNY 44,572,950.98 in the previous year[20]. - Basic and diluted earnings per share for Q1 2022 were both CNY 0.0109, compared to CNY 0.0216 in Q1 2021[21]. - Other comprehensive income after tax for Q1 2022 was CNY -6,609,059.44, compared to CNY 13,995,956.56 in Q1 2021[20]. Cash Flow - The net cash flow from operating activities increased by 61.43% to ¥136,125,499.12, compared to ¥82,294,323.13 in the same period last year[3]. - The net cash flow from operating activities for Q1 2022 was ¥136,125,499.12, an increase of 61.5% compared to ¥84,323,093.26 in Q1 2021[23]. - Total cash inflow from investment activities was ¥215,492,136.98, significantly lower than ¥1,257,468,268.82 in the same period last year[23]. - The net cash flow from investment activities was -¥270,159,931.02, compared to -¥130,179,235.91 in Q1 2021, indicating a deeper cash outflow[23]. - Cash inflow from financing activities totaled ¥226,749,600.00, up from ¥200,000,000.00 in Q1 2021[24]. - The net cash flow from financing activities was ¥24,331,603.16, a decrease of 87.6% compared to ¥195,778,361.10 in the previous year[24]. - The ending balance of cash and cash equivalents was ¥490,328,338.90, down from ¥1,030,802,501.45 at the end of Q1 2021[24]. - The total cash outflow from operating activities was ¥455,524,810.67, compared to ¥333,694,758.21 in Q1 2021, reflecting a 36.5% increase[23]. - The company received tax refunds amounting to ¥11,994,861.31, compared to ¥5,542,048.67 in the previous year[23]. - The cash paid to employees was ¥57,968,689.28, an increase from ¥45,764,762.46 in Q1 2021[23]. - The impact of exchange rate changes on cash and cash equivalents was -¥1,539,578.01, compared to ¥589,162.18 in Q1 2021[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,462,015,211.26, a slight increase of 0.55% from the previous year[4]. - The company's current assets totaled CNY 1,998,820,428.78, compared to CNY 1,946,365,405.27 at the beginning of the year, reflecting an increase of approximately 2.5%[15]. - Cash and cash equivalents decreased to CNY 539,934,275.71 from CNY 761,564,289.06, representing a decline of about 29.1%[15]. - Inventory increased to CNY 768,324,073.23 from CNY 714,771,672.65, marking a rise of approximately 7.5%[15]. - Short-term borrowings rose to CNY 272,749,600.00 from CNY 246,000,000.00, indicating an increase of about 10.9%[16]. - The total liabilities as of March 31, 2022, were CNY 518,624,674.74, compared to CNY 498,926,461.51 at the beginning of the year, reflecting an increase of approximately 3.5%[16]. - Total liabilities as of the end of Q1 2022 were CNY 574,109,232.37, an increase from CNY 558,277,304.57 at the end of Q1 2021[20]. - Total equity attributable to shareholders of the parent company was CNY 4,869,042,013.17, slightly up from CNY 4,851,211,464.04 year-over-year[20]. Operational Challenges and Plans - The company's gross profit margin decreased due to logistics disruptions caused by the pandemic, affecting sales structure[4]. - The company plans to continue expanding its overseas pharmaceutical intermediate sales despite challenges in logistics[4]. - The company is facing delays in project commissioning due to the pandemic, affecting the installation and debugging of equipment for several projects[12]. - The company plans to invest CNY 18,040.25 million in a project in Cambodia to produce 10,000 tons of aniline, aimed at enhancing product lines and reducing production costs[12]. - A total of CNY 9,450 million is allocated for the construction of a project producing hydroquinone and other products, which is expected to improve product structure and create new profit growth points[12]. - The company has invested CNY 6,500 million in a project for adhesive production in Cambodia, which is intended to extend the existing industrial chain[13]. Cost and Expenses - Total operating costs for Q1 2022 were CNY 407,517,431.69, up 20.83% from CNY 337,035,488.15 in the same period last year[19]. - Research and development expenses for Q1 2022 were CNY 9,216,795.92, a decrease from CNY 9,876,478.73 in the same period last year[20]. - The company's financial expenses surged by 2,127.51% to ¥288.24, primarily due to increased exchange rate losses[8].

Financial Performance - The company reported a total impairment provision of 890.115 million yuan for the year 2021, resulting in a net profit attributable to shareholders of the listed company being negative [5]. - The company's operating revenue for 2021 was CNY 2,235,302,787.80, a decrease of 6.17% compared to CNY 2,382,275,010.61 in 2020 [22]. - The net profit attributable to shareholders was CNY -791,202,027.47, representing a decline of 511.43% from CNY 202,223,912.92 in 2020 [22]. - The net cash flow from operating activities was CNY 92,683,406.31, down 18.33% from CNY 178,527,341.01 in the previous year [22]. - The total assets at the end of 2021 were CNY 5,431,979,242.78, a decrease of 18.40% from CNY 6,546,796,225.98 at the end of 2020 [22]. - The company reported a basic earnings per share of CNY -0.3836, a decline of 511.59% compared to CNY 0.0980 in 2020 [22]. - The net profit after deducting non-recurring gains and losses was CNY -807,769,517.50, a significant drop from CNY 83,358,134.00 in 2020 [22]. - The company faced a loss in 2021 due to an asset impairment provision of CNY 89,011.50 million, despite stable production and sales [46]. Market and Industry Context - The pharmaceutical industry is undergoing significant changes due to new policies and the ongoing impact of the COVID-19 pandemic, presenting both challenges and opportunities for the company [5]. - The domestic pharmaceutical excipients market only accounts for 3%-5% of the total pharmaceutical formulation output value, compared to 10%-20% in foreign markets, indicating significant growth potential for the excipients industry [34]. - The domestic pharmaceutical industry is undergoing structural changes due to intensified competition and regulatory improvements, benefiting high-quality excipients manufacturers [35]. - The company is positioned to leverage the growing demand for high-quality pharmaceutical products as consumer expectations for safety and efficacy increase [35]. Strategic Initiatives and Acquisitions - The company acquired 80% and 20% stakes in Yuxingkang Company for CNY 44 million during the reporting period [22]. - The company completed the acquisition of Henan Yuxing Pharmaceutical Co., Ltd. for ¥44,000,000.00, gaining 100% ownership [85]. - The acquisition of Inner Mongolia New Minghai Technology Co., Ltd. was completed for ¥17,500,000.00, with a 78.95% ownership stake [85]. - The company is expanding its strategic layout in upstream and downstream industries, particularly in composite excipients and pharmaceutical intermediates, to enhance market competitiveness [48]. Research and Development - The company is actively involved in the research and development of new excipients, catering to the diverse and personalized needs of downstream formulation clients [39]. - The company’s R&D investment amounted to ¥49,018,677.67 in 2021, representing 2.19% of operating revenue, an increase from 2.02% in 2020 [73]. - The number of R&D personnel increased to 159 in 2021, a 0.63% rise from 158 in 2020, with a proportion of 9.86% of total employees [73]. - The company is focusing on enhancing its investment projects in Cambodia, which are expected to become significant profit growth points in the future [96]. Governance and Management - The company has established a fair and transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with relevant laws and regulations [109]. - The company maintains independent operations in terms of assets, personnel, finance, and business, with no instances of fund occupation by the controlling shareholder [110]. - The company has a complete governance structure with independent operation of the board, supervisory board, and other internal institutions [111]. - The company has established independent financial accounting systems and does not share bank accounts with the controlling shareholder [110]. Environmental and Social Responsibility - The company reported a total environmental protection expenditure of 20.486 million yuan in 2021, with 15.088 million yuan allocated to environmental engineering projects [158]. - The company has established a wastewater treatment station equipped with an online monitoring system to ensure compliance with discharge standards [155]. - The company actively supports local agricultural initiatives, purchasing 2,000 pounds of pears to alleviate local farmers' sales pressure [162]. - The company emphasizes the importance of social responsibility, focusing on the integration of corporate and social benefits to promote harmonious development with employees and society [159]. Financial Management and Risks - The company has implemented measures to mitigate foreign exchange risks associated with its overseas projects and procurement activities [101]. - The company is addressing potential risks from macro policy adjustments in the pharmaceutical industry by optimizing its operational strategies [99]. - The company has established a robust internal control system to enhance governance and risk management, ensuring compliance and operational efficiency [145]. - The company has no overdue or unrecovered funds from entrusted financial management, with a total of CNY 984 million in bank financial products [191].